Chief Financial Officer · Apogee Therapeutics, Inc. (APGE)

Jane Henderson

A named executive officer of Apogee Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$855,900

Salary $540,000Stock awards $0

FY2024: $5,079,510

2nd of 3 named executive officers at Apogee Therapeutics by FY2025 total.

3 named officers on file for Apogee Therapeutics, FY2025

Jane Henderson’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • APGE’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Apogee Therapeutics’s whole pay program stands against its peers

  • Apogee Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on APGE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2026 (DEF 14A).

Free

Get Jane Henderson’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jane Henderson compensation by year

Apogee Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Apogee Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$469,311$525,000$540,000
Bonus$374,332$0$0
Stock awards$881,270$0$0
Option awards$3,300,000$4,200,135$0
Non-equity incentive$0$354,375$315,900
Pension and deferred compensation$0$0$0
All other$0$0$0
Total$5,024,913$5,079,510$855,900

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Apogee Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001193125-26-177342, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Apogee Therapeutics, Inc. filed document, accession 0001193125-26-177342. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.

$5.0M
$5.1M
$856K
FY23
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsOption awards

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU60,338$4,554,312—
Option87,673—$22.86
Option93,722—$49.07

Per the Outstanding Equity Awards at Fiscal Year-End table in Apogee Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Apogee Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Michael HendersonChief Executive Officer$1,291,500
Jane Henderson · this pageChief Financial Officer$855,900
Carl DambkowskiChief Medical Officer$855,900

The full Apogee Therapeutics compensation record

free company brief

This page is one person within Apogee Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Apogee Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Apogee Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jane Henderson's compensation dossier · One-time report. No refunds.